Cecilia Jiménez Mallebrera
Jefe de Grupo Senior
Research group
Researcher Cecilia Jiménez graduated in Biology from the University of Navarra and from the University of Buckingham in 1996 and earned her PhD in Genetics from the University of London (UCL) in 2001. In 2005, she obtained the degree of Clinical Scientist for the Health and Care Professions Council of the United Kingdom.
Between 2001 and 2010, she undertook a postdoctoral stay at the Dubowitz Neuromuscular Center (now in Great Ormond Street Hospital, London) and the Dept. Of Neuropathology at the Charing Cross Hospital, London where she specialized in neuromuscular pathologies and in the genetics and mechanisms of congenital muscular dystrophies.
She is a member of the European networks EURO-NMD and Treat-NMD and CIBERER.
In 2010, she joined as Researcher Miguel-Servet and group leader at the FSJD.
She is currently leading the group of applied research in neuromuscular diseases whose main objectives are to deepen the mechanism by which neuromuscular diseases occur, to improve the diagnosis of patients by identifying new biomarkers and methodologies and to investigate advanced therapies based, among others, on the genetic edition.
Professional network profiles
Related websites
SJD Barcelona Children's Hospital Last Publications
- Badosa-Gallego MC, Roldan-Molina M, Fernández-Irigoyen J, Santamaria E and Jimenez-Mallebrera C Proteomic and functional characterisation of extracellular vesicles from collagen VI deficient human fibroblasts reveals a role in cell motility. SCIENTIFIC REPORTS . 13(1): 14622-14622.
- Codina-Bergadà A, Roldan-Molina M, Natera-de Benito D, Ortez-Gonzalez CI, Planas R, Matalonga L, Cuadras-Palleja D, Carrera-García L, Exposito-Escudero JM, Márquez-Pereira JM, Jimenez-Mallebrera C, M Porta J, Nascimento-Osorio A and Jou-Munoz C Innovative Computerized Dystrophin Quantification Method Based on Spectral Confocal Microscopy INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 24(7): .
- Trifunov S, Natera-de Benito D, Carrera-García L, Codina-Bergadà A, Exposito-Escudero JM, Ortez-Gonzalez CI, Medina J, Torres Alcala S, Bernal S, Alias L, Badosa-Gallego MC, Balsells S, Alcolea D, Nascimento-Osorio A and Jimenez-Mallebrera C Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen Journal of neuromuscular diseases . 10(4): 653-665.
Projects
- Project name:
- Role of CMG2 and its associated effectors as potential therapeutic targets and in the pathophysiology of congenital muscular dystrophies due to collagen VI deficiency
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Alexion Pharmaceuticals Inc.
- Code
- PCP00387
- Starting - finishing date:
- 2023 - 2026
- Project name:
- Cerrando la brecha terapeutica para Distrofias Musculares Congenitas. Estrategias para mejorar la eficacia, liberacion y seguridad de terapias basadas en CRISPR/Cas9 y oligonucleotidos
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Fundación Noelia. Niños Contra la Distrofia Muscular Congénita por Déficit de Colágeno VI
- Code
- PFNR0182
- Starting - finishing date:
- 2023 - 2025
- Project name:
- Cerrando la brecha terapeutica para Distrofias Musculares Congenitas. Estrategias para mejorar la eficacia, liberacion y seguridad de terapias basadas en CRISPR/Cas9 y oligonucleotidos
- Leader
- Cecilia Jiménez Mallebrera
- Funding entities:
- Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD, Jiménez Mallebrera, Cecilia
- Code
- PI22/01382
- Starting - finishing date:
- 2023 - 2025
News
-
Characterization of Extracellular Vesicles in Fibroblasts of Collagen-VI Related Muscular Dystrophy
A team led by the Applied research in neuromuscular diseases at the Institut de Recerca Sant Joan de Déu · SJD Barcelona Children's Hospital has made significant advancements in comprehending the pathogenesis of Collagen-VI Related Muscular Dystrophy (COL6-RD) by analyzing extracellular vesicles and their correlation with cellular mobility.
-
Gene therapy proved against Muscular Distrophy with the ALBA Synchrotron
A study by the Institut de Recerca Sant Joan de Déu, ICFO, CIBERER and the ALBA Synchrotron has helped demonstrate that gene therapy can reverse the effects of the mutation that causes the symptoms of congenital muscular dystrophy in patient cells.
-
Sant Joan de Déu participates in the new Barcelona Medical Photonics Network
Eight prominent health institutions in the Barcelona area, their research institutes and ICFO join forces through the creation of a network to bring cutting-edge photonic technologies to hospitals.